| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Departments of Oral Biology and 2 Pathology, Immunology & Laboratory Medicine, PO Box 100424, University of Florida, Gainesville, FL 32610
* corresponding author, scha{at}dental.ufl.edu
Sjögren's Syndrome (SS) is a chronic autoimmune disease characterized by histological and functional alterations of salivary and lacrimal glands that result in a severe dryness of the mouth and the eyes. The etiology of SS has remained undefined despite investigators' significant efforts to identify the mechanisms of initiation. Based on histopathology, several animal models are available—such as MRL/lpr, NZW/NZB, NFS/sld, graft vs. host, transgenic mouse expressing viral surface antigen, and the non-obese diabetic (NOD) mouse—for investigation of the etiology of SS. Biochemical and immunological similarities between human SS and autoimmune exocrinopathy (AEC) in the NOD mouse, including the loss of secretory function, establish the NOD mouse as an appropriate model to unravel the underlying pathophysiology of SS. Recently, several NOD congenic partner strains have been developed to investigate the roles of genetic intervals, cytokines, and autoantibodies in the disease pathogenesis. Studies on NOD-scid suggest that the pathogenesis of SS occurs in two phases: an asymptomatic phase, in which epithelial cells of exocrine tissues undergo dedifferentiation accompanied by elevated apoptosis; and a second phase in which autoaggression is mounted against target organ autoantigens, resulting in the activation of T- and B-cells, and the generation of autoantibodies. The presence of autoantibodies on the cell-surface signaling receptor, the muscarinic3 receptor, in both SS patients and the NOD mice correlates with the hallmark clinical symptom of secretory dysfunction. Additionally, the NOD mouse model provides an important example of how both Th1 and Th2 cytokines, as well as non-immune genetic loci, are involved in the maintenance of and progression to the overt disease state. Ultimately, analysis of these data provides insight into potentially novel therapeutic interventions.
Key words. Sjögren's syndrome, autoimmune exocrinopathy, animal models, NOD mice, pathogenesis
This article has been cited by other articles:
|
|
 |
|
  M. E. Doyle, L. Boggs, R. Attia, L. R. Cooper, D. R. Saban, C. Q. Nguyen, and A. B. Peck Autoimmune Dacryoadenitis of NOD/LtJ Mice and Its Subsequent Effects on Tear Protein Composition Am. J. Pathol., October 1, 2007; 171(4): 1224 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Q. Nguyen, H. Kim, J. G. Cornelius, and A. B. Peck Development of Sjogren's Syndrome in Nonobese Diabetic-Derived Autoimmune-Prone C57BL/6.NOD-Aec1Aec2 Mice Is Dependent on Complement Component-3 J. Immunol., August 15, 2007; 179(4): 2318 - 2329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Q. Nguyen, J.-h. Gao, H. Kim, D. R. Saban, J. G. Cornelius, and A. B. Peck IL-4-STAT6 Signal Transduction-Dependent Induction of the Clinical Phase of Sjogren's Syndrome-Like Disease of the Nonobese Diabetic Mouse J. Immunol., July 1, 2007; 179(1): 382 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B M Lodde, B J Baum, P P Tak, and G Illei Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment Ann Rheum Dis, November 1, 2006; 65(11): 1406 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B M Lodde, F Mineshiba, J Wang, A P Cotrim, S Afione, P P Tak, and B J Baum Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome Ann Rheum Dis, February 1, 2006; 65(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| IADR Journals | Advances in Dental Research ® | Journal of Dental Research ® | Critical Reviews (1990-2004) |
